Endocrinology ·
Abbott sets December launch for Libre Duo sensor; 21-day CGM shows 8.4% MARD in children; DBLG1 holds 72% time in range
Listen to this post
read by AI voices · all episodesTHE SHORT READ
Abbott said Oct. 21 that it plans a December U.S. launch of its Libre Duo glucose-ketone sensor. A real-world study reported 8.4% mean absolute relative difference for a 21-day continuous glucose monitor in children with type 1 diabetes, and a 12-month evaluation of the DBLG1 hybrid closed loop held median time in range near 72%.
THE DETAILS
- Technology Oct 21, 2026Abbott plans to launch its Libre Duo dual-analyte sensor, which tracks glucose and ketones, in the U.S. this December, the company said with its third-quarter earnings report, Drug Delivery Business reported Oct. 21. The sensor received an Food and Drug Administration (FDA) de novo authorization in August, and its international debut is set for this fall. Chief Executive Robert Ford said additional reimbursement coverage for the system in type 1 diabetes goes into effect Jan. 1. Ford also said the company is starting a clinical trial of a lactate sensor.Source: Drug Delivery Business
- Technology Oct 21, 2026The Instara-1 21-day continuous glucose monitoring system had an overall mean absolute relative difference of 8.4%, a median absolute relative difference of 5.4% and a correlation of 0.965 with paired capillary reference glucose values (2,386 pairs in the primary analysis) in a real-world evaluation in pediatric type 1 diabetes, according to a study published Oct. 21 in BMJ Open Diabetes Research & Care. The authors said extended-wear sensors may reduce device burden and concluded that the system showed clinically acceptable real-world accuracy in children with type 1 diabetes.Sources: BMJ Open Diabetes Research & Care, PubMed
- Research Oct 19, 2026Median time in range with the latest version of the DBLG1 hybrid closed-loop software, paired with the Kaleido patch pump, was 72.0%, 72.3%, 72.0% and 71.7% at three, six, nine and 12 months in a 12-month prospective evaluation in 2,014 adults with type 1 diabetes across Europe, according to a study published Oct. 19 in Diabetes, Obesity and Metabolism. The authors said the meal period is critical for automated insulin delivery outcomes and concluded that the study demonstrates sustained safety and effectiveness of the software. The study was funded by Diabeloop SA.Sources: Diabetes, Obesity and Metabolism, PubMed
The weekly innovation roundup for endocrinology, published every Sunday for the week before; every item links to its sources. Latest endocrinology news · All specialties